Clinical Trial: Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion.

U.S., Jan. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07361224) titled 'Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion.' on Jan. 04.

Brief Summary: This is a Phase 1, single-center, open-label study to evaluate the safety of CLS-015 in combination with anti-CD19 CAR-T therapy in patients with large B-cell lymphoma. The goal is to improve clinical response by reversing the negative effects of NETs on immune function and CAR-T cells.

Study Start Date: Feb., 2026

Study Type: INTERVENTIONAL

Condition: Large B-Cell Lymphoma (LBCL)

Intervention: DRUG: rhDNase I

CLS-015 I...